MENU
+Compare
NVCR
Stock ticker: NASDAQ
AS OF
Nov 28 closing price
Price
$12.81
Change
+$0.05 (+0.39%)
Capitalization
1.43B

NVCR NovoCure Limited Forecast, Technical & Fundamental Analysis

NovoCure Ltd is an oncology company with a propreitary platform technology in United States... Show more

NVCR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for NVCR with price predictions
Nov 28, 2025

NVCR's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for NVCR turned positive on November 21, 2025. Looking at past instances where NVCR's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NVCR's RSI Indicator exited the oversold zone, of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on November 20, 2025. You may want to consider a long position or call options on NVCR as a result. In of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NVCR advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

NVCR moved below its 50-day moving average on October 30, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NVCR crossed bearishly below the 50-day moving average on November 05, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVCR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NVCR broke above its upper Bollinger Band on November 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NVCR entered a downward trend on November 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NVCR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.203) is normal, around the industry mean (63.404). P/E Ratio (0.000) is within average values for comparable stocks, (37.294). NVCR's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.720). NVCR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (2.204) is also within normal values, averaging (36.108).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVCR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
NVCR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

NVCR is expected to report earnings to rise 47.82% to -48 cents per share on February 19

NovoCure Limited NVCR Stock Earnings Reports
Q4'25
Est.
$-0.49
Q3'25
Beat
by $0.09
Q2'25
Beat
by $0.02
Q1'25
Beat
by $0.18
Q4'24
Missed
by $0.25
The last earnings report on October 30 showed earnings per share of -33 cents, beating the estimate of -41 cents. With 736.14K shares outstanding, the current market capitalization sits at 1.43B.
A.I. Advisor
published General Information

General Information

a commercial-stage oncology company

Industry MedicalNursingServices

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
Grenville Street
Phone
+44 1534756700
Employees
1453
Web
https://www.novocure.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BERIX14.26N/A
N/A
Carillon Chartwell Real Income I
LCEIX20.13N/A
N/A
Invesco Diversified Dividend Investor
AIAFX27.07N/A
N/A
abrdn Global Infrastructure A
FBOGX9.93N/A
N/A
Templeton Global Smaller Comp R6
FBKFX17.61N/A
N/A
Fidelity Balanced K6

NVCR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NVCR has been loosely correlated with BLFS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NVCR jumps, then BLFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCR
1D Price
Change %
NVCR100%
+0.39%
BLFS - NVCR
39%
Loosely correlated
-0.67%
ALGN - NVCR
38%
Loosely correlated
-0.03%
AZTA - NVCR
38%
Loosely correlated
-1.96%
TWST - NVCR
37%
Loosely correlated
+0.98%
ENOV - NVCR
36%
Loosely correlated
-0.13%
More

Groups containing NVCR

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVCR
1D Price
Change %
NVCR100%
+0.39%
Medical/Nursing Services
industry (215 stocks)
38%
Loosely correlated
+0.77%
Health Services
industry (422 stocks)
2%
Poorly correlated
+0.44%